But still a long way, before India gives the world its first new molecule
NCE research by its very nature is a long drawn out process, but Indian pharma is slowly learning to be patient for the long term, high risk drug discovery model. This will surely translate it into a NCE superpower in years to come...
A question looming large on the face of the
Indian Pharma industry is, when will India give to the world its first new molecule? Well, my belief is, that while it is unlikely to happen in the immediate future, it will surely happen over a period of 8-10 years. This belief stems from the significant position carved by the Indian pharma industry in the global generics marketplace and the progress made by leading pharma companies in their drug discovery programs.
Over the years, Indian Pharma Industry has acquired expertise in low cost manufacturing while complying with the highest standards of quality and regulatory processes. Companies like DRL, Ranbaxy, Lupin, Glenmark, Cipla et al have contributed immensely in bringing down the healthcare costs by providing quality generics at affordable prices. But still, the scenario for Indian pharma companies is challenging as they have to grow their generics business, as well as continue to invest in drug discovery and maintain sustainable growth & profitability.
Selling generics in the advanced markets requires a whole culture of Intellectual Property Management to be built within the company. Few Indian companies including Lupin have successfully challenged patents of the innovators, which have opened the revenue streams through exclusive marketing rights. Moreover, a large number of Para IV filings are currently pending with the USFDA.
NCE research by its very nature is a long drawn out process, but Indian pharma is slowly learning to be patient for the long term, high risk drug discovery model. This will surely translate it into a NCE superpower in years to come...
A question looming large on the face of the
Indian Pharma industry is, when will India give to the world its first new molecule? Well, my belief is, that while it is unlikely to happen in the immediate future, it will surely happen over a period of 8-10 years. This belief stems from the significant position carved by the Indian pharma industry in the global generics marketplace and the progress made by leading pharma companies in their drug discovery programs.Over the years, Indian Pharma Industry has acquired expertise in low cost manufacturing while complying with the highest standards of quality and regulatory processes. Companies like DRL, Ranbaxy, Lupin, Glenmark, Cipla et al have contributed immensely in bringing down the healthcare costs by providing quality generics at affordable prices. But still, the scenario for Indian pharma companies is challenging as they have to grow their generics business, as well as continue to invest in drug discovery and maintain sustainable growth & profitability.
Selling generics in the advanced markets requires a whole culture of Intellectual Property Management to be built within the company. Few Indian companies including Lupin have successfully challenged patents of the innovators, which have opened the revenue streams through exclusive marketing rights. Moreover, a large number of Para IV filings are currently pending with the USFDA.
4 comments:
i agree with you ,Companies like DRL, Ranbaxy, Lupin, Glenmark, Cipla et al have contributed immensely in bringing down the healthcare costs by providing quality generics at affordable prices
this article is great
the iipm magazines rockz
indian pharma industry is on high
Post a Comment